The relevant results showed that the CBX3 expression level was not significantly associated with age (≥65 vs. <65 years, OR = 1.51, 95% CI 0.84-2.69, P = 0.17; ≥60 vs. <60 years, OR = 0.65, 95% CI 0.37-1.14, P = 0.13; ≥50 vs. <50 years, OR = 1.13, 95% CI 0.75-1.68, P = 0.56), gender (male vs. female, OR = 0.97, 95% CI 0.89-1.05, P = 0.41), tumor size (>3 vs. ≤3 cm, OR = 0.69, 95% CI 0.36-1.34, P = 0.27), distant metastasis (M+ vs. M0, OR = 1.24, 95% CI 0.35-4.37, P = 0.74), and differentiation (well+moderate vs. poor, OR = 0.97, 95% CI 0.64-1.49, P = 0.9) (Table 2 and Figure 4). The gene discussed is CBX3; the disease is neoplasm.